Method of detection of clinically significant post-prandial hyperglycemia in normoglycemic patients

Abstract

This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and / or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction. An increased AHB level at fasting baseline and an elevated glucose level of at least about 155 mg / dL at 30 minutes and / or 1 hour indicates that a normoglycemic, normo-insulinemic and / or non-dyslipidemic patient has developed or has an increased likelihood of developing clinically significant post-prandial hyperglycemia.

Description

[0001]PRIORITY CLAIM[0002]This application is a continuation of U.S. patent application Ser. No. 14 / 154,074 filed Jan. 13, 2014 which claims priority to U.S. Provisional Application No. 61 / 751,328, filed Jan. 11, 2013, U.S. Provisional Application No. 61 / 831,337, filed Jun. 5, 2013, and U.S. Provisional Application No. 61 / 831,405, filed Jun. 5, 2013, the entirety of each of which are incorporated herein by reference and relied upon.BACKGROUND[0003]Currently a number of tests exist that can diagnose patients as diabetic or pre-diabetic, including pre-diabetic conditions, such as occult pancreatic beta cell dysfunction or post-prandial hyperglycemia. Such tests include glucose, insulin, pro-insulin, c-peptide, HbA1c, fructosamine, glycation gap, 1,5-anhydroglucitol (1,5-AG), OGTT, CLIX scoring, HOMA IR scoring, and IRI scores based on combinations of AHB, L-GPC, and Oleic Acid weighted by insulin or BMI. Used alone or in combination some of these tests can detect the presence of Type ...

AI Technical Summary

Benefits of technology

This patent text describes a method for determining the health risk of a patient with pancreatic beta cell dysfunction and providing treatment guidance based on the results of various tests. The treatment guidance can include suggestions for further testing, drug therapy, lifestyle changes, and avoidance of certain medications. The method can also involve the use of antioxidants, anti-coagulants, anti-dyslipidemics, and other agents to treat the condition. Overall, the patent text presents a detailed approach for assessing and treating patients with pancreatic beta cell dysfunction.

Problems solved by technology

Most OGTTs and CLIX scoring require a patient to remain in the doctor's office for 2 hours post dose, and most clinicians only test baseline samples and the 2-hour time point, and not the labor-intensive 3-5 additional times blood draws during the 2-hour period necessary for CLIX scoring, due to labor and cost constraints.

Additionally, complicated and laborious mathematical calculations need to be performed in order to optimize detection of at-risk individuals with these techniques, and kidney function (approximated by blood creatinine levels / eGFR) needs to be accounted for, causing an additional step.

Images